Contact Information
  • 800-826-HOPE (4673)
Cy Aaron Stein, M.D., Ph.D.
  • Clinical Professor and Researcher, Medical Oncology

Professional Experience

  • 2012 - Present, Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • 2012 - 2014, Arthur and Rosalie Kaplan Chair and Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA
  • Series Editor:  Perspectives in Antisense Science (Kluwer Academic Publishers; four volumes published)
  • Editorial Advisory Boards:  Associate Editor: Cancer Gene Therapy (Stockton Press) Molecular Cancer Therapeutics (American Association for Cancer Research) Clinical Cancer Research (American Association for Cancer Research) Molecular Therapy (American Society for Gene Therapy)
  • Current Scientific Advisory Boards and Consultancies Santaris (Copenhagen, DK); Tekmira-Protiva (Vancouver, BC); Gentium, S.p.A. (Como, Italy); Nanoviricides (West Haven, CT);
  • Former Consulting Chief Medical Officer, Tokai Pharmaceuticals (2009-10, Cambridge, MA) Lead compound, currently in a Phase 1/2 clinical trial is TOK-001 for castrate-resistant prostate cancer
  • 2003 - 2012, Professor of Medicine, Urology and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY
  • 2003 - 2012, Attending Physician and Director, Medical Genitourinary Oncology, Montefiore Medical Center, Bronx, NY
  • 1993-2011, Co-Editor-in-Chief: Oligonucleotides (formerly Antisense and Nucleic Acid Drug Development and Antisense Research and Development; Mary-Ann Liebert Publishers)
  • 1992 - 2003, Assistant and Associate Professor of Pharmacology and Medicine, Columbia University, College of Physicians and Surgeons, New York, NY
  • 1990 - 1992, Assistant Professor of Medicine, Columbia University, College of Physicians and Surgeons, New York, NY
  • 1988 - 1990, Senior staff fellow, National Cancer Institute, Bethesda, MD


  • 1985 - 1988, Clinical Associate, National Cancer Institute, Bethesda, MD
  • 1983 - 1985, Internal medicine resident, The New York Hospital-Cornell Medical Center, New York, NY
  • 1982 - 1983, Internal medicine intern, The New York Hospital-Cornell Medical Center, New York, NY
  • 1982, Albert Einstein College of Medicine (AECOM) Bronx, NY, Awarded M.D.
  • 1978, Stanford University, Stanford, CA, Ph.D., Organic Chemistry
  • 1974, Brown University, Providence, RI, B.A

Board Certifications/Licensure
  • California Medical License
  • Maryland Medical License
  • New York State Medical License
  • 1986, Diplomate, American Board of Internal Medicine
  • 1987, Diplomate, American Board of Oncology


  • 1992 - 1995, American Cancer Society, Clinical Career Development Award

  • 2013, Top Doctors in the LA Area (Oncology), Pasadena Magazine
  • 2010 & 2011, Who’s Who in the World (Marquis)
  • 2009, Faculty of 1000 Biologists Selection
  • 2009, Who’s Who in America (Marquis)
  • 2008, 2009, 2011, Best Doctors in New York, New York Magazine
  • 2008 - 2009, New York’s “Super Doctors” (top 5%), New York Times Magazine
  • 2004 - 2011, Best Doctors in the NY Metro Area, Castle Connolly Medical Ltd., publisher
  • 2000, European Journal of Pharmaceutics and Biopharmaceutics, best paper of 1999



  • American  Society for Clinical Oncology
  • American Association for Cancer Research
  • American Society for Gene Therapy (Oligonucleotide Therapeutics Committee, 2005-2008)


1. Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R., and Mani, S.  The bcl- 2-family of protein ligands as cancer drugs:  The next generation of therapuetics.  Curr. Med. Chem.-Anti-Cancer Agents,  2003 (3), 217-223.
2. Nichols, G. and Stein, C.A. “Modulation of the activity of bcl-2 in Waldenstrom’s Macroglobulinemia using antisense oligonucleotides” Semin. Oncol. 2003, (30) 297-299.
3.  Wang, L., Prakash, R., Stein, C.A., Koehn, R., and Ruffner, D.  “Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo”, Antisense and Nucleic Acid Drug Development, 2003 (13) 169-189
4. Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides.  Ann. NY Acad Sci., 2003 (1002).
5. Stein, C.A., Dias, N., Benimetskaya, L, Jepsen, J., Lai, J., and Raffo, A. “LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides With Pleotropic Mechanisms of Action.” Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.
6. Stein, C.A., Mani, S., Benimetskaya, L. “Combinations of Chemotherapy with Antisense Approaches Against bcl-2”, in Combination Cancer Therapy:  Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228
7. Stein, C.A., Benimetskaya, L., and Mani, S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898. 
8. Stein, C.A. and Rossi, J. “A Critical Assessment of the Potential of Short Interfering RNA Therapeutics’, Drug Discovery Today: Technologies, 2005,; (2) 27-31.
9. Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides—Transcriptonal and Translational Strategies for Silencing Gene Expression.  Ann. NY Acad Sci., 2005 (1058)
10. Benimetskaya, L., Lai, J., Khvorova, A., Wu, S., Miller, P. and Stein, C.A.  “Induction of Apoptosis by G3139 in Melanoma Cells”, Ann. NY Acad. Sci, 2005 (1058) 235-245.
11. Stein, C.A., Benimetskaya, L., and Mani, S.  “Antisense Strategies for Oncogene Inactivation”, Semin. Oncol. 2005, (32) 563-572.
12. Kornblum, N., Ayyanar, K., Benimetskaya, L., Richardson, P., Iacobelli, M., and Stein, C.A. “Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action”, Oligonucleotides, 2006 (16), 105-114.
13. Stein, C.A. “The Genasense ‘Learning Curve’”, Letter to the Editor, Nature Biotechnology, 2007 (25) 972-973.
14. Stein, C.A.  “Genasense: It Ain’t Over Till the Fat Lady Sings”, Editorial, Oligonucleotides, 2007 (17) 345-348.
15. Stein, C.A. Kornblum, N., Lai, J., and Benimetskaya, L. “Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action”.  In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42 
16. Stein, C.A., Benimetskaya, L., Kornblum, N., and Mani, S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.
17. Stein, C.A., and Colombini, M.  “Specific VDAC Inhibitors:  Phosphorothioate Oligonucleotides” J. Bioenerg. Biomemb., 2008, 40:157-162.
18. Stein, C.A., Hoehn, B., and Rossi, J.  “Oligonucleotide Therapeutics”  In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.
19. Stein, C.A., and Soifer, H. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.
20. Soifer, H., Koch, T., Hansen, B., Hoeg, A., Oerum, H., and Stein, C.A. “Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides” in M. Kaufmann and C. Klinger, eds., Functional Genomics:  Methods and Protocols: Methods in Molecular Biology, 815:333-346 Springer Press, 2011.
21. Stein, C.A., and Goel, S.  “Therapeutic Oligonucleotides—The Road Not Taken”, invited commentary in Clinical Cancer Research, 2011, 17:6369-6372.
22. Twardowski, P. and Stein, C.A. “Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors”., July 2, 2012
23. Hu, J., Hsu, J., Bergerot, P., Yuh, B., Stein, C.A., and Pal, S.  “Preoperative therapy for localized prostate cancer: A comprehensive overview”, Maturitas, 2013, 74:3-9.
24. Pal, S., Stein, CA, Sartor, O. “Enzalutamide for the treatment of prostate cancer,” Expert Opinion in Pharmacotherapy, 2013, (14), 679-685
25. Eroglu, Z., Stein, C.A., Pal, S.  “Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.\


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010